Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Clarithromycin
Drug ID BADD_D00480
Description Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.
Indications and Usage An alternative medication for the treatment of acute otitis media caused by H. influenzae, M. catarrhalis, or S. pneumoniae in patients with a history of type I penicillin hypersensitivity. Also for the treatment of pharyngitis and tonsillitis caused by susceptible Streptococcus pyogenes, as well as respiratory tract infections including acute maxillary sinusitis, acute bacterial exacerbations of chronic bronchitis, mild to moderate community-acquired pneuomia, Legionnaires' disease, and pertussis. Other indications include treatment of uncomplicated skin or skin structure infections, helicobacter pylori infection, duodenal ulcer disease, bartonella infections, early Lyme disease, and encephalitis caused by Toxoplasma gondii (in HIV infected patients in conjunction with pyrimethamine). Clarithromycin may also decrease the incidence of cryptosporidiosis, prevent the occurence of α-hemolytic (viridans group) streptococcal endocarditis, as well as serve as a primary prevention for Mycobacterium avium complex (MAC) bacteremia or disseminated infections (in adults, adolescents, and children with advanced HIV infection).
Marketing Status approved
ATC Code J01FA09
DrugBank ID DB01211
KEGG ID D00276
MeSH ID D017291
PubChem ID 84029
TTD Drug ID D0Z1ZM
NDC Product Code 49452-2112; 46708-344; 46708-345; 57237-044; 61919-643; 71335-1493; 0781-6023; 65096-0100; 53002-7561; 65862-226; 0527-1932; 76420-051; 27241-064; 43063-530; 68071-5045; 68788-8480; 0527-1930; 57237-045; 60687-435; 63187-376; 63187-625; 71335-1567; 38779-1937; 63415-0018; 43063-942; 53002-7562; 62332-345; 68788-7933; 0527-1931; 62991-2687; 51655-668; 65862-225; 0781-6022; 43666-0001; 60592-429; 50090-5285; 67296-1072; 67296-1360; 68071-3116; 70518-2773; 71335-0017; 72189-299; 0781-1961; 15894-0026; 27241-065; 62135-615; 62135-616; 62332-344; 0591-2805; 59566-0123; 50090-5282; 50268-178; 50268-179; 64380-906; 67296-0464; 68071-2869; 0781-1962; 43063-752; 43063-823; 64380-905; 68788-7125; 0904-6872; 43781-0403; 51552-1566; 50090-1830
UNII H1250JIK0A
Synonyms Clarithromycin | 6-O-Methylerythromycin | TE-031 | TE 031 | TE031 | A-56268 | A 56268 | A56268 | Biaxin
Chemical Information
Molecular Formula C38H69NO13
CAS Registry Number 81103-11-9
SMILES CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N( C)C)O)(C)OC)C)C)O)(C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pharyngeal erythema22.04.05.0100.000558%Not Available
Pneumatosis intestinalis07.11.01.0430.000670%Not Available
Loss of proprioception17.02.07.0190.000447%Not Available
Hypoaesthesia oral17.02.06.021; 07.05.05.0030.001340%Not Available
Paraesthesia oral07.05.05.035; 17.02.06.0080.000335%Not Available
Bipolar disorder19.16.01.003--Not Available
Toxic skin eruption23.03.05.003; 10.01.01.008; 12.03.01.0730.001228%Not Available
Retroperitoneal haematoma24.07.01.060; 07.07.02.0050.000335%Not Available
Nuchal rigidity15.05.04.005; 17.05.02.006--Not Available
Skin oedema23.06.04.0010.000223%Not Available
Angiopathy24.03.02.007--Not Available
Epidermal necrosis23.03.03.035--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Drug resistance08.06.01.0050.001787%Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Feeding disorder19.09.01.003; 14.03.02.0030.000447%Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Inflammation10.02.01.089; 08.01.05.0070.001228%Not Available
Limb discomfort15.03.04.0140.000447%Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Nasal mucosal disorder22.04.03.0090.000558%Not Available
Optic neuropathy17.04.05.005; 06.02.08.0020.000558%Not Available
Spondylitis15.01.09.0020.000223%Not Available
Temperature regulation disorder05.03.04.013; 08.05.01.0040.000223%Not Available
Abnormal behaviour19.01.01.001--Not Available
Decreased appetite08.01.09.028; 14.03.01.005--
The 17th Page    First    Pre   17 18 19 20 21    Next   Last    Total 21 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene